FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2004349871> ?p ?o ?g. }

• W2004349871 endingPage "388" @default.
• W2004349871 startingPage "383" @default.
• W2004349871 abstract "<h3>Aim:</h3> To describe our experience in treating vitreoretinal involvement of primary central nervous system lymphoma, by intravitreal injections of methotrexate (MTX). <h3>Methods:</h3> Patients with suspected intraocular lymphoma underwent a diagnostic vitrectomy. Samples were sent for cytology, genetic evaluation and for interleukin level measurements. Treatment protocol included injection of 400 μg/0.1 ml MTX intravitreally twice weekly for 4 weeks, once weekly for 8 weeks, and then once monthly for 9 months, for a total of 25 injections. Data were collected from the patients’ records and included, inter alia, response to intravitreal MTX measured by time to disappearance of vitreal cells and retinal infiltrates, changes in visual acuity, and clinical recurrence rate. <h3>Results:</h3> In the past 10 years we have treated 44 eyes of 26 patients; seven patients had monocular involvement, and 19 binocular. Six patients were initially diagnosed as having a non-responsive uveitis, and 16 with either CNS or systemic lymphoma with later involvement of the eye. Four patients had systemic lymphoma; one of them was found to have CNS lymphoma after the ocular involvement. Three patients had T cell lymphoma, and the rest had B cell lymphoma. Clinical remission was reached after 6.4 (3.4) (2–16) injections of MTX (mean (SD) (range)), with 95% of the eyes needing 13 injections or less to be cleared of malignant cells. None of the patients had an intraocular recurrence. Among the side effects, the most common was corneal epitheliopathy, which usually appeared after the third injection and began to subside when the intervals between injections increased. <h3>Conclusions:</h3> Vitreoretinal involvement of lymphoma can be controlled effectively and without serious adverse reactions by intravitreal MTX injections. The treatment protocol described herein has resulted in no intraocular recurrence so far and has had bearable side effects. The accumulating clinical results bring us to propose the consideration of this protocol as a good first-line treatment option for intraocular lymphoma." @default.
• W2004349871 created "2016-06-24" @default.
• W2004349871 creator A5020728015 @default.
• W2004349871 creator A5023982171 @default.
• W2004349871 creator A5055040314 @default.
• W2004349871 creator A5081265839 @default.
• W2004349871 creator A5085559437 @default.
• W2004349871 date "2008-02-26" @default.
• W2004349871 modified "2023-10-01" @default.
• W2004349871 title "Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience" @default.
• W2004349871 cites W1533530670 @default.
• W2004349871 cites W1759464676 @default.
• W2004349871 cites W1974277693 @default.
• W2004349871 cites W1979179383 @default.
• W2004349871 cites W1988295204 @default.
• W2004349871 cites W1991937689 @default.
• W2004349871 cites W1996666810 @default.
• W2004349871 cites W2006043159 @default.
• W2004349871 cites W2009155233 @default.
• W2004349871 cites W2018712601 @default.
• W2004349871 cites W2018913264 @default.
• W2004349871 cites W2022787156 @default.
• W2004349871 cites W2024828959 @default.
• W2004349871 cites W2033363456 @default.
• W2004349871 cites W2038184167 @default.
• W2004349871 cites W2040843391 @default.
• W2004349871 cites W2049578895 @default.
• W2004349871 cites W2070901154 @default.
• W2004349871 cites W2088552509 @default.
• W2004349871 cites W2088624983 @default.
• W2004349871 cites W2090661457 @default.
• W2004349871 cites W2106961673 @default.
• W2004349871 cites W2129524501 @default.
• W2004349871 cites W2142855426 @default.
• W2004349871 cites W2160843661 @default.
• W2004349871 cites W2165439369 @default.
• W2004349871 cites W2328500891 @default.
• W2004349871 cites W85915734 @default.
• W2004349871 doi "https://doi.org/10.1136/bjo.2007.127928" @default.
• W2004349871 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18303160" @default.
• W2004349871 hasPublicationYear "2008" @default.
• W2004349871 type Work @default.
• W2004349871 sameAs 2004349871 @default.
• W2004349871 citedByCount "223" @default.
• W2004349871 countsByYear W20043498712012 @default.
• W2004349871 countsByYear W20043498712013 @default.
• W2004349871 countsByYear W20043498712014 @default.
• W2004349871 countsByYear W20043498712015 @default.
• W2004349871 countsByYear W20043498712016 @default.
• W2004349871 countsByYear W20043498712017 @default.
• W2004349871 countsByYear W20043498712018 @default.
• W2004349871 countsByYear W20043498712019 @default.
• W2004349871 countsByYear W20043498712020 @default.
• W2004349871 countsByYear W20043498712021 @default.
• W2004349871 countsByYear W20043498712022 @default.
• W2004349871 countsByYear W20043498712023 @default.
• W2004349871 crossrefType "journal-article" @default.
• W2004349871 hasAuthorship W2004349871A5020728015 @default.
• W2004349871 hasAuthorship W2004349871A5023982171 @default.
• W2004349871 hasAuthorship W2004349871A5055040314 @default.
• W2004349871 hasAuthorship W2004349871A5081265839 @default.
• W2004349871 hasAuthorship W2004349871A5085559437 @default.
• W2004349871 hasConcept C118487528 @default.
• W2004349871 hasConcept C126322002 @default.
• W2004349871 hasConcept C141071460 @default.
• W2004349871 hasConcept C2776194053 @default.
• W2004349871 hasConcept C2778007619 @default.
• W2004349871 hasConcept C2778257484 @default.
• W2004349871 hasConcept C2779338263 @default.
• W2004349871 hasConcept C2781059491 @default.
• W2004349871 hasConcept C2781242345 @default.
• W2004349871 hasConcept C71924100 @default.
• W2004349871 hasConceptScore W2004349871C118487528 @default.
• W2004349871 hasConceptScore W2004349871C126322002 @default.
• W2004349871 hasConceptScore W2004349871C141071460 @default.
• W2004349871 hasConceptScore W2004349871C2776194053 @default.
• W2004349871 hasConceptScore W2004349871C2778007619 @default.
• W2004349871 hasConceptScore W2004349871C2778257484 @default.
• W2004349871 hasConceptScore W2004349871C2779338263 @default.
• W2004349871 hasConceptScore W2004349871C2781059491 @default.
• W2004349871 hasConceptScore W2004349871C2781242345 @default.
• W2004349871 hasConceptScore W2004349871C71924100 @default.
• W2004349871 hasIssue "3" @default.
• W2004349871 hasLocation W20043498711 @default.
• W2004349871 hasLocation W20043498712 @default.
• W2004349871 hasOpenAccess W2004349871 @default.
• W2004349871 hasPrimaryLocation W20043498711 @default.
• W2004349871 hasRelatedWork W1967181837 @default.
• W2004349871 hasRelatedWork W2046455257 @default.
• W2004349871 hasRelatedWork W2049418513 @default.
• W2004349871 hasRelatedWork W2069529760 @default.
• W2004349871 hasRelatedWork W2090267842 @default.
• W2004349871 hasRelatedWork W2270140377 @default.
• W2004349871 hasRelatedWork W2359184673 @default.
• W2004349871 hasRelatedWork W2375770616 @default.
• W2004349871 hasRelatedWork W2399983929 @default.
• W2004349871 hasRelatedWork W2434859484 @default.
• W2004349871 hasVolume "92" @default.

• next